We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Psynova Neurotech and Roche Collaborate on Schizophrenia Companion Diagnostic

By LabMedica International staff writers
Posted on 10 Dec 2009
Psynova Neurotech Ltd. More...
(Cambridge, UK), a subsidiary of Rules-Based Medicine, Inc. (RBM; Austin TX, USA) has entered into an exclusive research and licensing agreement with Roche to collaborate on the discovery, development, validation, and commercialization of diagnostic immunoassays to aid the clinical development and commercial differentiation of novel treatments for schizophrenia.

Roche will contract Psynova to identify candidate serum protein biomarkers that can be used for the prognosis of disease progression and predicting or monitoring the efficacy and safety of a compound from Roche's central nervous system (CNS) pipeline. Psynova will utilize its proprietary schizophrenia biomarker panels, its extensive central nervous system (CNS) disease database and its access to RBM's DiscoveryMAP technology to identify a specific biomarker signature that could serve as a companion diagnostic. Any resulting companion diagnostic will be developed either by Psynova and RBM (as the preferred developer for the companion diagnostic in partnership with Roche), or independently by Roche (Basel, Switzerland), which would result in milestone and royalty payments to Psynova.

Psynova Neurotech, together with the Bahn laboratory Inc., at the University of Cambridge Institute of Biotechnology (UK) and RBM recently announced the discovery and characterization of a combination of protein biomarkers that demonstrate utility as an adjunctive aid in the differential diagnosis of schizophrenia.

Rules-Based Medicine, Inc. is a clinical laboratory improvement amendments (CLIA)-certified biomarker testing laboratory that solves complex diagnostic, therapeutic development, and treatment challenges. The Company's proprietary multianalyte profiling (MAP) platform makes the drug discovery and development process more efficient and effective by providing preclinical and clinical researchers with reproducible, quantitative, multiplexed, immunoassay data for hundreds of proteins from small sample volumes.

Schizophrenia symptoms can include hallucinations, delusions, disordered thinking, movement disorders, flat affect, social withdrawal, and cognitive deficits, and are often undistinguishable from those of other mental health or central nervous system illnesses. Treatments can relieve many symptoms of schizophrenia and allow people to live independent lives. Biomarkers have the potential to facilitate identification of patients that will benefit from specific treatments and monitor their responses during treatment.

Related Links:

Psynova Neurotech Ltd.
Rules-Based Medicine, Inc.
Roche
University of Cambridge Institute of Biotechnology



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.